{
    "clinical_study": {
        "@rank": "151342", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine if oxycodone and naltrexone combination\n      capsules (ALO-02) have the potential to be abused when they are crushed and snorted."
        }, 
        "brief_title": "A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Abuse Liability Study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  Non-dependent, recreational opioid users.  (Must use opioid for non-therapeutic\n             purposes on at least 10 occassions within the last year and at least once in the 8\n             weeks before Visit 1 (Screening Visit).\n\n          -  Must have experience with intranasal opioid administration (snorted opioid drugs on\n             at least 3 occassions within the last year before Visit 1 (Screening Visit).\n\n        Exclusion Criteria:\n\n          -  Diagnosis of substance and/or alcohol dependence\n\n          -  Subject has participated in, is currently participating in, or seeking treatment for\n             substance and/or alcohol related disorder."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775189", 
            "org_study_id": "B4531009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "description": "crushed sugar spheres (powder) x 1 dose", 
                "intervention_name": "ALO-02 weight-matched placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "crushed ALO-02 30 mg/3.6 mg capsule x 1 dose", 
                "intervention_name": "crushed ALO-02 30 mg/3.6 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "description": "crushed lactose tablets (powder) x 1 dose", 
                "intervention_name": "oxycodone weight-matched placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "description": "Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose", 
                "intervention_name": "crushed oxycodone IR 30 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naltrexone", 
                "Oxycodone", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Relative abuse potential study", 
            "Chronic pain", 
            "oxycodone", 
            "naltrexone", 
            "opioid-related disorders", 
            "drug abusers"
        ], 
        "lastchanged_date": "September 11, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531009&StudyName=A%20Study%20to%20Characterize%20the%20Abuse%20Liability%20of%20ALO-02%20in%20Healthy%2C%20Non-Dependent%2C%20Recreational%20Opioid%20Users%20When%20ALO-02%20Capsules%20are%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5V 2T3"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Single-Dose, 4-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Intranasally to Non-Dependent, Recreational Opioid Users", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "High: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "High: Peak Effect (Emax)", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775189"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "High: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "High: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "High: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Take drug again visual analogue scale (VAS) is a subjective assessment of the degree to which a participant would desire to take the drug again if given the opportunity. It is presented on a 100-point VAS with score ranging from 0 to 100 (score of 0 =", 
                "measure": "Take Drug Again:  Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "12, 24 h post-dose"
            }, 
            {
                "measure": "Take Drug Again:  Mean Effect (Emean)", 
                "safety_issue": "No", 
                "time_frame": "12, 24 h post-dose"
            }, 
            {
                "description": "Overall Drug Liking VAS assesses the participant's global perception of drug liking (that is, effects over the whole course of the drug experience including any carryover effects). A 100-point VAS is used to assess response based on a score ranging from 0 to 100 (0 =", 
                "measure": "Overall Drug Liking:  Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "12, 24 h post-dose"
            }, 
            {
                "measure": "Overall Drug Liking:  Mean Effect (Emean)", 
                "safety_issue": "No", 
                "time_frame": "12, 24 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Any Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Any Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Any Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Any Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Good Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Good Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Good Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Bad Drug Effects: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Bad Drug Effects: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Feel Sick: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Feel Sick: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Feel Sick: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Feel Sick: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Nausea: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Nausea: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Nausea: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Nausea: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Sleepy: Area Under Effect Curve (AUE) From 0-8 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Sleepy: Area Under Effect Curve (AUE) From 0-24 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Dizzy: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100). AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Dizzy: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Any Drug Effects: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Good Drug Effects: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Bad Drug Effects: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Feel Sick: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Nausea: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Sleepy: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).", 
                "measure": "Dizzy: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "A 6-point scale assessing 5 categories: burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion.", 
                "measure": "Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-1 Hour for \"burning\"", 
                "safety_issue": "Yes", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Subject Rating Scale for Nasal Effects: Area Under Effect Curve (AUE) From 0-2 Hours for \"burning\"", 
                "safety_issue": "Yes", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Subject Rating Scale for Nasal Effects: Peak Effect (Emax) for \"burning\"", 
                "safety_issue": "Yes", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Subject Rating Scale for Nasal Effects: Time to Maximum (Peak) Effect (TEmax) for \"burning\"", 
                "safety_issue": "Yes", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "description": "Weight of drug powder remaining (if any) after dosing.", 
                "measure": "Percentage of dose (drug powder) insufflated", 
                "safety_issue": "No", 
                "time_frame": "up to 5 min post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-1) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-1).", 
                "measure": "Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-2) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-2).", 
                "measure": "Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-8) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-8).", 
                "measure": "Pupillometry: Area Under Effect Curve (AUE) From 0-8 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions. AUE (0-24) = Area under the effect versus time curve from time zero to time of last quantifiable effect (0-24).", 
                "measure": "Pupillometry: Area Under Effect Curve (AUE) From 0-24 Hours", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions.", 
                "measure": "Pupillometry: Peak Effect (Emax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Pupillometry assessments measure change in pupil size (miosis) as an indicator of opioid pharmacological properties.  Participants have the size of pupil measured using a pupillometer. Measurements are made in a dimly lit (mesopic) room with controlled lighting conditions.  TEmax = Time to smallest post-dose pupil size.", 
                "measure": "Pupillometry: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100-point bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of", 
                "measure": "Drug Liking: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "High VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "High: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Any Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Any Drug Effects: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Good Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Good Drug Effects: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Bad Drug Effects VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Sleepy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Sleepy: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Dizzy VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Dizzy: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Nausea VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Nausea: Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Feel Sick VAS assesses the effect experienced by the participant on a 100-point unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0) to 'extremely' (score of 100).  TEmax = Time to maximum observed score.", 
                "measure": "Feel Sick:  Time to Maximum (Peak) Effect (TEmax)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Oxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Oxymorphone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Noroxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of Naltrexone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) of 6-beta-naltrexol", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Oxymorphone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Noroxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of Naltrexone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) of 6-beta-naltrexol", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2) of Oxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of Oxymorphone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of Noroxycodone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of Naltrexone", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) of 6-beta-naltrexol", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "description": "AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area Under the Oxycodone Concentration-Time Curve (AUC0-1h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Area Under the Oxymorphone Concentration-Time Curve (AUC0-1h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Area Under the Noroxycodone Concentration-Time Curve (AUC0-1h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Area Under the Naltrexone Concentration-Time Curve (AUC0-1h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-1h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1 h post-dose"
            }, 
            {
                "measure": "Area Under the Oxycodone Concentration-Time Curve (AUC0-2h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Area Under the Oxymorphone Concentration-Time Curve (AUC0-2h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Area Under the Noroxycodone Concentration-Time Curve (AUC0-2h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Area Under the Naltrexone Concentration-Time Curve (AUC0-2h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-2h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2 h post-dose"
            }, 
            {
                "measure": "Area Under the Oxycodone Concentration-Time Curve (AUC0-8h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "measure": "Area Under the Oxymorphone Concentration-Time Curve (AUC0-8h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "measure": "Area Under the Noroxycodone Concentration-Time Curve (AUC0-8h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "measure": "Area Under the Naltrexone Concentration-Time Curve (AUC0-8h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "measure": "Area Under the 6-beta-naltrexol Concentration-Time Curve (AUC0-8h)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Oxycodone Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Oxymorphone Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Noroxycodone Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Naltrexone Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable 6-beta-naltrexol Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 h post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}